|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16-Nov-2020 |
TrialSite News: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product
|
|
|
TrialSite News, the digital media news site dedicated to coverage of clinical research trials, reported the following, “Australian clinical-stage drug development company Noxopharm (ASX: NOX) is pleased to announce it has joined with Bristol Myers Squibb (NYSE: BMY) in an Australian pilot study investigating the ability of Noxopharm’s immunotherapy drug candidate, Veyonda®, to overcome resistance to Bristol Myers Squibb’s nivolumab (Opdivo®) in the treatment of cancer.”
Click here to read more
|
|
|
|
|
|
|
|
|
12-Nov-2020 |
BioWorld: Other news to note for Nov. 12, 2020
|
|
|
BioWorld, in its Other News to Note section said,” Noxopharm Ltd., of Sydney, is partnering with Bristol Myers Squibb Co., of New York, to study Noxopharm's sphingosine-1-phosphate inhibitor, Veyonda, in cancer patients who have developed a resistance to BMS’ Opdivo (nivolumab). The study, called Iconic-1, will start recruiting patients early in 2021.”
Click here to read more
|
|
|
|
|
|
|
|
|
|
8-Oct-2020 |
BioWorld: In the clinic for Oct. 8, 2020
|
|
|
BioWorld, in its In The Clinic section, reported on Noxopharm's NOXCOVID trial first COVID patient's treatment; "Treated first patient in Noxcovid-1 study enrolling subjects hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care and mechanical ventilation".
Click here to read more
|
|
|
|
21-Aug-2020 |
BioWorld: Other news to note for Aug. 18, 2020
|
|
|
Global biotech news service, BioWorld, in its Other News To Note, covered Noxopharm's reporting (11 Aug 2020) that, " Independent research published in European Urology Oncology showed the combination of 177Lu-PSMA-617 radioligand therapy and Veyonda (idronoxil), its sphingosine-1-phosphate inhibitor, was safe and effective, with median overall survival (OS) of 17.1 months in late-stage prostate cancer patients who exhausted standard treatment options. Median OS in a study conducted in a comparable population who received standard chemotherapy was 4.5 months."
Click here to read more.
|
|
|
|
|
18-Aug-2020 |
PharmaVOICE: Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates
|
|
|
PharmaVOICE.com provided the news release, "Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates" which reported that the Australian clinical-stage drug development company announced the publication of the first manuscript of the LuPIN trial in the journal, European Urology Oncology. This journal is the first official publication of the European Association of Urology that is fully devoted to the study of genitourinary cancer.
Click here to read more.
|
|
|
|
|
23-Jul-2020 |
BioWorld: Other news to note for July 23, 2020
|
|
|
BioWorld notes in its section Other News to Note for July 23,2020, "Noxopharm Ltd reported preclinical data from two independent research groups confirming that idronoxil, the active ingredient in the company's immuno-oncology drug candidate, and sphingosine-1-phosphate inhibitor, Veyonda, activate cancer-fighting immune cells and then enable their entry into microtumors. Noxopharm said other preclinical and clinical data, together with the new research data, leads the company to believe it is close to claiming the first drug capable of converting tumors from cold to hot across multiple cancer types in a well-tolerated way"
Click here to read more.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|